Skip to main content
. 2019 Jul 5;27(9):1558–1567. doi: 10.1016/j.ymthe.2019.06.013

Figure 2.

Figure 2

CGX1321 Liposome Formulation Changes Its Pharmacokinetics In Vivo

(A) Liposome-CGX1321 size distribution by Malvern particle size analyzer. (B) CGX1321 liposome stability analysis in vitro in the presence of 10% serum in PBS (pH 7.4); CGX1321 remaining in the dialysis tube was tested at different times points. (C) The pharmacokinetic curves of CGX1321 in D5W oral formulation or liposome formulations. Pharmacokinetic studies were done in GA007 xenograft mouse models; plasma was collected and CGX1321 concentration was measured at multi-time points (N = 3). (D) CXG1321 distribution in tumors from GA007 PDX mouse model (n = 3). CGX1321 concentrations were measured by LC-MS at multiple times post-dosing of liposome or D5W-formulated CGX1321. (E and F) Immunofluorescence staining in tumor (E) and intestine (F) from GA007 PDX mouse model after a single dosing of 10 mg/kg liposome-CGX1321 (liposome concentration is 50 mg/mL) via i.v. injection, detected by confocal microscopy. Scale bar, 25 μm.